SSG
BIIB icon

Summit Securities Group’s Biogen BIIB Stock Holding History

Summit Securities Group’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-500
Closed -$97K – 649
2024
Q3 		$97K Buy
+500
New +$105K 0.03% 187
2024
Q2 		– Sell
-800
Closed -$173K – 586
2024
Q1 		$173K Buy
+800
New +$187K 0.03% 165
2020
Q3 		– Sell
-30
Closed -$803K – 371
2020
Q2 		$803K Buy
+30
New +$9.02K 0.1% 173
2020
Q1 		– Sell
-10
Closed -$297K – 309
2019
Q4 		$297K Buy
+10
New +$2.77K 0.02% 353

Other funds holding BIIB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Summit Securities Group's BIIB Position: Q2 2026 in Review

Summit Securities Group increased its Biogen (BIIB) stake by 42% in Q2 2026, buying an estimated $1.91K and bringing the position to 34 shares worth $7.35K. The position accounts for ﹤0.01% of the portfolio, ranked #899.

Summit Securities Group first reported a position in BIIB in Q1 2016 and has held it in 15 quarters since. The position peaked at $1.71M in Q1 2016. 1,046 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • Summit Securities Group held 34 shares of Biogen worth $7.35K as of Q2 2026.
  • Summit Securities Group bought 10 Biogen shares in Q2 2026, an estimated $1.91K.
  • Biogen made up ﹤0.01% of Summit Securities Group's portfolio in Q2 2026, its #899 holding.
  • Summit Securities Group first reported a position in Biogen in Q1 2016 and has held it in 15 quarters since.
  • Summit Securities Group's Biogen position peaked at $1.71M in Q1 2016.
  • 1,046 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Summit Securities Group's 13F filing for Q2 2026, filed 3 Aug 2026.